Nature Medicine | Spoonful of Medicine

Stanford program gives discoveries a shot at commercialization

By Mike May In the late 1990s, Daria Mochly-Rosen, a protein chemist at the Stanford University School of Medicine in California, discovered that a certain class of drugs that inhibit enzymes known as protein kinase C could reduce cardiac damage after a heart attack. Working with Stanford’s Office of Technology Licensing (OTL), she patented the finding with hopes of licensing it to a pharmaceutical company. No one showed any interest. Determined, Mochly-Rosen made the rounds with her colleagues in the pharmaceutical industry. But her pharma contacts wanted a drug to prevent heart attacks, not something to give after them. “They 

BACK TO ARTICLE

Your details are incomplete or incorrect, please amend the following information

%s

Tell a Friend

Your friend's email address (Required)

Your email (Required)

Message subject (Required)

Message

Verify (Required)

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE